Active Treatment in High-Risk, Early-Stage CLL or SLL

H&O How often do patients present with asymptomatic, early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and how many of these patients experience progression […]

The Sequencing of Covalent and Noncovalent BTK Inhibitors in CLL

H&O What are the most important differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors? JW The covalent BTK inhibitors that have US Food and […]

Fixed-Duration vs Continuous Treatment for Chronic Lymphocytic Leukemia in the CLL17 Trial

H&O What was the impetus for the CLL17 trial? OA Over the past 5 to 10 years, we have seen the evolution of 2 treatment paradigms […]